Oculis Publishes Invitation to the Annual General Meeting
Rhea-AI Summary
Oculis (Nasdaq: OCS) published its invitation to the 2026 Annual General Meeting, to be held May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, with in-person attendance and a broadcast (no virtual participation).
Shareholders on Nasdaq US will receive physical proxy materials; Nasdaq Iceland shareholders may submit electronic voting instructions via the Lumi AGM platform. A shareholder information session with management is scheduled for May 11, 2026 in Reykjavík and via webcast; meeting materials and replays are available on the investor website.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – OCS
On the day this news was published, OCS gained 1.24%, reflecting a mild positive market reaction. This price movement added approximately $20M to the company's valuation, bringing the market cap to $1.66B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
OCS gained 4.19% while peers were mixed: QURE up 3.09%, EYPT up 1.34%, ABUS down 2.34%, TSHA down 0.31%, UPB flat. No concentrated, same-direction sector move is evident.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 08 | Insider RSU notice | Neutral | -0.6% | Routine RSU vesting disclosure for a director with minor share-price impact. |
| Apr 07 | Conference participation | Positive | +0.2% | Announcement of investor conferences and highlighting upcoming pivotal readouts. |
| Mar 31 | Regulatory designation | Positive | +8.3% | EMA PRIME designation for Privosegtor following prior breakthrough and orphan statuses. |
| Mar 27 | Executive equity grant | Neutral | -0.6% | Annual equity incentive awards for an executive with limited market reaction. |
| Mar 16 | Clinical presentation | Positive | +1.6% | Planned Phase 2 ACUITY results presentation for Privosegtor at NANOS 2026. |
Recent history shows routine governance and insider items causing minimal moves, while positive regulatory or clinical news, such as EMA PRIME designation, coincided with a stronger upside reaction.
Over the last month, Oculis issued several routine governance and participation updates with muted price reactions (around flat moves after PDMR and conference notices). In contrast, the Mar 31 EMA PRIME designation for Privosegtor saw a stronger +8.31% move. Today’s AGM invitation is another governance-related update, and it follows a period where only clearly value-adding clinical or regulatory milestones have triggered more pronounced price responses.
Regulatory & Risk Context
An effective Form F-3 dated Nov 10, 2025 registers the resale of up to 494,259 ordinary shares issuable upon warrant exercise. Oculis is not selling shares under this prospectus and would only receive up to $6,877,246.59 in warrant exercise proceeds if exercised in cash. No usage of this shelf has been recorded.
Market Pulse Summary
This announcement outlines logistics for Oculis’s 2026 AGM on May 13, 2026 and a shareholder information session on May 11, 2026. Recent history shows that governance and meeting notices have had limited standalone impact, while events like the EMA PRIME designation on Mar 31 coincided with a stronger move. Investors may focus more on upcoming clinical milestones than on the mechanics of meeting participation.
AI-generated analysis. Not financial advice.
ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), today published the invitation to the 2026 Annual General Meeting, which will be held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 6:00 a.m. EDT / 10:00 a.m. GMT / 12:00 p.m. CEST.
The 2026 Annual General Meeting will be held in-person and broadcast, with no option for virtual participation. To join the broadcast, please use the following link: https://meetings.lumiconnect.com/100-352-684-319.
Information pertaining to the 2026 Annual General Meeting, including meeting materials, can be accessed on our website at https://investors.oculis.com/events-presentations.
Shareholders holding shares traded on Nasdaq US will receive physical proxy materials and voting instructions.
Shareholders holding shares traded on Nasdaq Iceland will not receive physical proxy materials and may instead submit their voting instructions electronically via the Lumi AGM Mobile Platform provided by Lumi Global. To register for voting of your shares traded on Nasdaq Iceland, please access the following link: www.lumiconnect.com/events/oculisagm2026.
Shareholder Information Session
Oculis will host an information session for all shareholders on Monday, May 11, 2026 at Hilton Reykjavík Nordica, Sudurlandsbraut 2, 108 Reykjavík, Iceland from 12:00-1:00 p.m. EDT / 4:00-5:00 p.m. GMT / 6:00-7:00 p.m. CEST, during which members of management will provide an overview of the 2026 Annual General Meeting proposals and answer questions from shareholders. To attend the shareholder information session either in person or virtually, please register via the following link: https://reg.lumiengage.com/oculis-agm-2026/informationsession. The webcast of the virtual information session will be available following the event by visiting our website at https://investors.oculis.com/events-presentations.
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); Licaminlimab, a novel, topical anti-TNFα in registrational trial, which is being developed with a genotype-based approach to drive precision medicine in dry eye disease (DED); and Privosegtor, a breakthrough neuroprotective candidate in the PIONEER program which consists of studies intended to support registration plans for treatment in optic neuropathies like optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases. Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com
